Tibsovo

Servier’s Tibsovo Gets FDA Approval as First Targeted Therapy for MDS
BioSpace
Wed, 10/25/23 - 09:41 am
Servier
Tibsovo
MDS
FDA
FDA starts speedy review of Servier's Tibsovo in MDS
Pharmaphorum
Thu, 08/17/23 - 09:58 am
Servier
IDH inhibitors
MDS
Tibsovo
FDA
priority reviews
Agios sells cancer drug royalty, raising $132M to fund rare disease mission
MedCity News
Fri, 10/28/22 - 10:23 am
Agios Pharmaceuticals
Tibsovo
ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe
Fierce Pharma
Sat, 12/11/21 - 09:15 pm
ASH2021
Servier
Tibsovo
AML
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
OBR Oncology
Wed, 11/24/21 - 10:23 am
ASH2021
CAR-T
lymphoma
Yescarta
Tibsovo
blood cancers
COVID-19
AML
With fresh FDA nod, Servier branches targeted drug Tibsovo into bile duct cancer
Fierce Pharma
Fri, 08/27/21 - 10:44 am
Servier
Tibsovo
bile duct cancer
FDA
Servier gets a win for cancer drug Tibsovo, bought in $1.8bn Agios deal
Pharmaforum
Mon, 08/2/21 - 09:39 pm
Servier
Agios
M&A
Tibsovo
AML
The 20 most expensive pharmacy drugs in the U.S. in 2020, from fallen blockbusters to new orphan meds
Fierce Pharma
Fri, 02/14/20 - 05:11 pm
drug pricing
Amryt Pharma
Myalept
Agios Pharmaceuticals
Tibsovo
ESMO: Agios celebrates milestone win for ivosidenib in tough-to-treat bile duct cancer
Fierce Pharma
Mon, 09/30/19 - 10:41 am
Agios
bile duct cancer
Tibsovo
ESMO
Agios Pharma's Tibsovo Shows Positive Results in Phase III for Another Cancer Indication
BioSpace
Thu, 05/16/19 - 06:44 pm
Agios Pharmaceuticals
Tibsovo
ivosidenib
clinical trials
cholangiocarcinoma